Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.

Tabassum, Neha; Zhang, Hua; Stebbing, Justin

Tabassum, Neha; Zhang, Hua; Stebbing, Justin.

Tabassum N; Department of Surgery and Cancer, Imperial College, London W12 0NN, UK.
Zhang H; Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, USA.
Stebbing J; Department of Surgery and Cancer, Imperial College, London W12 0NN, UK.

Cell Rep Med ; 1(8): 100145, 2020 11 17.

Article in English | MEDLINE | ID: covidwho-1065661

ABSTRACT

ABSTRACT

A screen by Kost-Alimova et al.1 suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Subject(s)

Acute Lung Injury/drug therapy; Aminopyridines/therapeutic use; COVID-19 Drug Treatment; Drug Repositioning; Morpholines/therapeutic use; Pyrimidines/therapeutic use; SARS-CoV-2/pathogenicity; Acute Lung Injury/etiology; Acute Lung Injury/metabolism; COVID-19/complications; COVID-19/metabolism; Humans; Mucin-1/metabolism; Respiratory Distress Syndrome/drug therapy; Respiratory Distress Syndrome/etiology; Respiratory Distress Syndrome/metabolism; Syk Kinase/antagonists & inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pyrimidines / Morpholines / Acute Lung Injury / Drug Repositioning / SARS-CoV-2 / COVID-19 Drug Treatment / Aminopyridines Topics: Long Covid Limits: Humans Language: English Journal: Cell Rep Med Year: 2020 Document Type: Article Affiliation country: J.xcrm.2020.100145

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google